Circulation: Is it necessary to prevent "sadness" while anthracyclines are used to treat cancer?

Anthracycline breast cancer adjuvant therapy and radiotherapy with or without anti-human epidermal growth factor receptor 2 antibody are related to cardiac insufficiency associated with cancer treatment
.

(PRADA during breast cancer adjuvant therapy in the prevention of heart failure) tests, and blood vessels of women angiotensin receptor blocker candesartan combination therapy can reduce breast cancer were treated with left ventricular ejection fraction (LVEF) reduced , Combined with the beta-blocker metoprolol can reduce the increase in cardiac troponin

Anthracycline breast cancer adjuvant therapy and radiotherapy with or without anti-human epidermal growth factor receptor 2 antibody .

This study aims to evaluate the long-term effects of candesartan and metoprolol or their combination on the prevention of reduced cardiac function and myocardial damage

This is a 2×2 factorial, randomized, placebo-controlled, double-blind, single-center trial in which patients with early breast cancer were randomized to receive candesartan cilexetil (32 mg) and metoprolol succinate (100 mg) Or a matching placebo combination therapy
.

The study drug was discontinued after adjuvant anticancer treatment

From a median of 23 months after randomization (interquartile range: 21-28 months), compared with baseline, the LVEF of each group at extended follow-up decreased slightly, but there was no significant difference (candesartan group 1.
7 %, 1.
8% in the non-candesartan group; 1.
6% in the metoprolol group and 1.
9% in the non-metoprolol group)
.

Compared with baseline, there was a small decrease in LVEF of each group at extended follow-up, but there was no significant difference

The occurrence of serious adverse events during the follow-up period of each group

The occurrence of serious adverse events during the follow-up period of each group

During adjuvant therapy, compared with candesartan treatment, treatment with candesartan was associated with a significant decrease in the patient’s left ventricular end-diastolic volume within 2 years (P=0.
021), and it also reduced the overall longitudinal strain reduction (P =0.
046)
.

Finally, there was no significant difference in the changes of cardiac troponin I and T concentrations in each group

During adjuvant therapy, compared with candesartan treatment, the use of candesartan treatment is associated with a significant reduction in the patient’s left ventricular end-diastolic volume within 2 years.

The results of this study indicate that for most early breast cancer patients without cardiovascular disease, extensive prophylactic cardioprotective therapy may not be required

For most non- cardiovascular patients with early breast cancer disease may not need to use a wide range of preventive cardioprotective therapy for the majority of non- cardiovascular patients with early breast cancer disease may not need to use a wide range of preventive cardioprotective treatment of cardiovascular

Original source:

Original source:

Siri Lagethon Heck, et al.

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2 × 2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol in this message